Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2018-06-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
国金证券股份有限公司关于公司2017年面向合格投资者公开发行公司债券（第一期）、2018年面向合格投资者公开发行公司债券（第一期）受托管理事务临时报告
Capital/Financing Update Classification · 95% confidence The document is a temporary report from Guojin Securities Co., Ltd. regarding the entrusted management affairs of bonds issued by Ruikang Pharmaceutical Co., Ltd. in 2017 and 2018. It includes credit rating information from a rating agency and updates on the bond credit ratings. The document references regulatory rules related to bond issuance and management, and it is clearly a report on bond trustee management activities rather than a full financial report, earnings release, or capital update. The document length is short (1655 characters) and it contains substantive information about bond credit ratings and trustee management, not just an announcement or certification. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities, including bond issuance and related trustee reports.
2018-06-27 Chinese
关于公司董事、监事和高管计划通过有限合伙企业增持公司股份完成的公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding the completion of a shareholding increase by the company's directors, supervisors, and senior management through a limited partnership. It details the number of shares acquired, the dates, and the amounts involved. The document references compliance with relevant laws and regulations and includes a commitment from the investing entity regarding trading behavior. There is no financial statement, earnings data, or detailed financial analysis present. The document is focused on insider share transactions and ownership changes by company executives. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 2116 characters, which is consistent with an announcement rather than a full report.
2018-06-26 Chinese
公司债券2018年跟踪评级报告
Audit Report / Information Classification · 95% confidence The document is a detailed credit rating report issued by a credit rating agency (联合信用评级有限公司) for 瑞康医药股份有限公司. It includes comprehensive financial data, credit ratings for the company and its bonds, detailed business and industry analysis, management and operational reviews, and future outlook. The report contains audited financial figures, business segment analysis, and risk factors. It is not a brief announcement or a simple notice but a full report on the company's credit status and financial health. This type of document fits the category of an Audit Report / Information (AR), as it is a standalone credit rating report with financial analysis and audit references, not a full annual report or earnings release. Therefore, the appropriate classification is AR with high confidence. Q1 2018
2018-06-25 Chinese
关于深圳证券交易所2017年年报问询函回复的公告
Annual Report Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shenzhen Stock Exchange regarding the company's 2017 annual report. It contains extensive financial data, explanations of revenue growth, cash flow analysis, credit policies, debt and financing details, goodwill impairment testing, and other comprehensive financial and operational information. The document is lengthy (15,000 characters) and includes substantive financial data and management explanations related to the annual report period. It is not a brief announcement or a certification letter but a detailed management reply to regulatory questions about the annual report. Therefore, it fits the category of an Annual Report (10-K) or equivalent detailed annual financial disclosure. Given the context and content, the best classification is Annual Report (10-K). FY 2017
2018-06-20 Chinese
关于公司2017年年报问询函的回复
Audit Report / Information Classification · 95% confidence The document is a detailed response to an inquiry letter regarding the 2017 annual report of 瑞康医药股份有限公司 (Ruikang Pharmaceutical Co., Ltd.). It is issued by the accounting firm 北京天圆全会计师事务所, which audited the company's 2017 annual report. The content includes detailed explanations about goodwill impairment testing, key parameters used in the impairment test, and evaluation reports from a professional appraisal firm. The document references the 2017 annual report specifically and provides substantive financial and audit-related data, including goodwill balances, impairment calculations, and valuation reports. This indicates it is an audit-related document focusing on the audit findings and responses to regulatory inquiries about the annual report, rather than the annual report itself or a simple announcement. It is not a certification letter or a brief announcement but a comprehensive audit response. Therefore, the document fits best into the category of Audit Report / Information (AR). FY 2017
2018-06-20 Chinese
2017年面向合格投资者公开发行公司债券（第一期）受托管理事务报告（2017年度）
Audit Report / Information Classification · 95% confidence The document is titled as a "2017年度受托管理事务报告" (2017 Annual Trustee Management Report) related to a corporate bond issuance by 瑞康医药股份有限公司 (Realcan Pharmaceutical Co., Ltd.). It contains detailed information about the bond issuance, terms, issuer's 2017 financial and operating status, use of raised funds, bondholder meetings, credit rating, and trustee management activities. The document is a comprehensive report on the trustee management of the bond issuance for the year 2017, including financial data and operational details, but it is not a full annual report (10-K) or an earnings release. It is also not a simple announcement or certification but a detailed report on the bond trustee management. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related financial information excluding full annual reports. The document is over 10,000 characters, indicating it is a full report, not just an announcement. Therefore, the best classification is AR with high confidence. FY 2017
2018-05-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.